A Non-Interventional, Retrospective, Observational Study to Analyze Safety, Efficacy and Tolerability of THINQURE 20 in COVID-19 Patients.

Thinq Pharma CRO Limited0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•We will consider the following criteria for retrospective analysis.
•1. Male or Female subjects of age 18 to 75 years (both inclusive).
•2. Subjects diagnosed with COVID-19 by RT-PCR.
•3. Patients provided oral & nasal swabs for test
•4. Females of child-bearing potential (i.e., who were not chemically or surgically sterilized or who were not post-menopause) must have had a negative urine pregnancy test.
•5. Females of child-bearing potential who have used a medically accepted method of contraception that was considered reliable in the judgment of the investigator.
•6. Subjects who have taken Thinqure 20 as prescribed by Investigator.

•Subjects were excluded on the following basis:
•1. Patients with a history of intracranial bleeding
•2. Patients without a completed medical history
•3. Patients, who were suffering from any haemoglobinopathies such as thalassemia that could interfere with oxygen carriage in the blood.
•4. Patients, who were smokers or consumed alcohol.
•5. Patients, who were suffering from active malignancy along with squamous cell or basal cell skin cancer.
•6. Female subjects who were pregnant or lactating or planning to become pregnant during the study period.
•7. Females who were not ready to use acceptable contraceptive methods during the course of study.

发起方